IDT Australia (ASX:IDT) Other Long-Term Liabilities: A$0.16 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is IDT Australia Other Long-Term Liabilities?

IDT Australia ASX:IDT -6.25% Other Long-Term Liabilities is A$0.16 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

IDT Australia's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.16 Mil.

IDT Australia's quarterly other long-term liabilities declined from Dec. 2024 (A$0.17 Mil) to Jun. 2025 (A$-0.00 Mil) but then increased from Jun. 2025 (A$-0.00 Mil) to Dec. 2025 (A$0.16 Mil).

IDT Australia's annual other long-term liabilities increased from Jun. 2023 (A$-0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then declined from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$-0.00 Mil).

IDT Australia Other Long-Term Liabilities Related Terms

IDT Australia Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for IDT Australia's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDT Australia Other Long-Term Liabilities Chart

IDT Australia Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 -0.00

IDT Australia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.00 0.17 -0.00 0.16

IDT Australia Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.16 Mil mean?
IDT Australia (ASX:IDT) has a Other Long-Term Liabilities of A$0.16 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on IDT Australia and its competitors.
Is IDT Australia's Other Long-Term Liabilities too high?
IDT Australia's current Other Long-Term Liabilities is A$0.16 Mil.
How does IDT Australia's Other Long-Term Liabilities compare to ZTS?
IDT Australia's Other Long-Term Liabilities of A$0.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on IDT Australia and its competitors. IDT Australia's current Other Long-Term Liabilities is A$0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.11, compared to a current price of A$0.05 — trading 59.1% below its estimated fair value. The current Other Long-Term Liabilities is A$0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Other Long-Term Liabilities is A$0.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IDT Australia Business Description

Address 45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.